The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Schott Pharma AG KGaA's Revenue for the
three
months ended in Mar. 2026 was $287 Mil. Schott Pharma AG KGaA's average Accounts Receivable for the
three
months ended in Mar. 2026 was $220 Mil.
Hence, Schott Pharma AG KGaA's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.30.
Schott Pharma AG KGaA (OTCPK:SHTPY) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Schott Pharma AG KGaA Receivables Turnover Related Terms
Schott Pharma AG KGaA Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Schott Pharma AG KGaA's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHTPY vs ISRG, BDX, MDLN: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Schott Pharma AG KGaA (SHTPY) has a Receivables Turnover of 1.30 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Schott Pharma AG KGaA and its competitors. According to the industry distribution chart, Schott Pharma AG KGaA ranks #423 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 52%.
Is Schott Pharma AG KGaA's Receivables Turnover too high?
Schott Pharma AG KGaA's current Receivables Turnover is 1.30. The Medical Devices & Instruments industry median Receivables Turnover is 5.55. Schott Pharma AG KGaA's value of 1.30 is 76.6% below this industry median. Based on the distribution chart, Schott Pharma AG KGaA ranks #423 out of 813 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Schott Pharma AG KGaA has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's Receivables Turnover compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #423 out of 813 companies for Receivables Turnover. This places Schott Pharma AG KGaA in the lower half of its industry. The industry median Receivables Turnover is 5.55. Schott Pharma AG KGaA's value of 1.30 is 76.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.55, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Schott Pharma AG KGaA's current Receivables Turnover of 1.30 is 76.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Schott Pharma AG KGaA and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current Receivables Turnover is 1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (SHTPY) has a current Receivables Turnover of 1.30. The stock's GF Value™ is $7.02, compared to a current price of $4.37 — trading 37.7% below its estimated fair value. The current Receivables Turnover is 1.30 and 76.6% below the Medical Devices & Instruments industry median of 5.55. Schott Pharma AG KGaA's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Schott Pharma AG KGaA (SHTPY), the current Receivables Turnover is 1.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (SHTPY) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of $4.37 is trading 37.7% below its estimated GF Value™ of $7.02.
Key valuation signals for SHTPY:
Receivables Turnover: 1.30
GF Value™: $7.02 vs. price of $4.37 (37.7% below fair value)
Industry Position: 76.6% below the Medical Devices & Instruments median (#423 of 813)
No single metric tells the full story. See the SHTPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
64GF Score
Get the complete analysis for SHTPY
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTPY has been successfully added to your 
